共 234 条
[1]
De Lima M(2004)Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 865-872
[2]
Anagnostopoulos A(2006)Hematopoietic stem-cell transplantation N Engl J Med 354 1813-1826
[3]
Munsell M(2012)Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011 Exp Hematol Oncol 1 13-536
[4]
Shahjahan M(2009)Busulfan in hematopoietic stem cell transplantation Biol Blood Marrow Tr 15 523-476
[5]
Ueno N(2002)Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Tr 8 468-864
[6]
Ippoliti C(2004)Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 104 857-110
[7]
Andersson BS(2007)Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients Biol Blood Marrow Tr 40 105-684
[8]
Gajewski J(2008)Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS Biol Blood Marrow Tr 14 672-547
[9]
Couriel D(2007)New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2 Bone Marrow Transplant 40 541-108
[10]
Cortes J(2010)Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide Korean J Hematol 45 102-940